v3.25.3
Insider Trading Arrangements
 3 Months Ended
Sep. 30, 2025
shares
Trading Arrangements, by Individual  
Material Terms of Trading Arrangement

Trading arrangement

During the quarter ended September 30, 2025, none of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated any “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408 of Regulation S-K for the purchase or sale of our securities, except as set forth below:

Name and Title

Type of Plan

Adoption or Termination Date

Plan Start Date

Plan End Date

Aggregate Number of Securities to be Sold

Description of Trading Arrangement

Lara Sullivan, M.D.
President, Chief Executive Officer and Chief Medical Officer

Rule 10b5-1 trading arrangement

Terminated on September 8, 2025

June 24, 2025

August 28, 2026

411,845(1)

Sales of shares intended to satisfy the affirmative defense of Rule 10b5-1(c)

Jakob Dupont,
Independent Board Members

Rule 10b5-1 trading arrangement

Adopted on September 24, 2025

September 24, 2025

December 31, 2026

180,000

Sales of shares intended to satisfy the affirmative defense of Rule 10b5–1(c)

 

(1) No shares were sold under this plan prior to its termination.

Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
Lara Sullivan [Member]  
Trading Arrangements, by Individual  
Name Lara Sullivan
Title M.D.President, Chief Executive Officer and Chief Medical Officer
Rule 10b5-1 Arrangement Terminated true
Termination Date September 8, 2025
Expiration Date August 28, 2026
Aggregate Available 411,845
Jakob Dupont [Member]  
Trading Arrangements, by Individual  
Name Jakob Dupont
Title Independent Board Members
Rule 10b5-1 Arrangement Adopted true
Adoption Date September 24, 2025
Expiration Date December 31, 2026
Aggregate Available 180,000